Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Study of LY2874455 in Participants With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01212107
Recruitment Status : Completed
First Posted : September 30, 2010
Results First Posted : June 12, 2019
Last Update Posted : June 12, 2019
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The study is to determine the recommended Phase 2 regimen of study drug that may be safely administered to participants with advanced and or metastatic cancer. The study consists of two parts: a dose escalation and a dose confirmation.

Condition or disease Intervention/treatment Phase
Advanced Cancer Drug: FGF Receptor Drug: Phosphate Binders Phase 1

Detailed Description:
Phase 1, first human dose study

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 94 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of LY2874455 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced Cancer.
Study Start Date : December 2010
Actual Primary Completion Date : August 2014
Actual Study Completion Date : February 2015

Arm Intervention/treatment
Experimental: Part A: 2 mg FGF Receptor QD

Part A: Dose escalation

2 milligrams (mg) FGF receptor given orally once daily (QD) for a minimum of (1) 28 day cycle.

If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Drug: FGF Receptor
LY2874455 administered orally.
Other Name: LY2874455

Experimental: Part A: 4 mg FGF Receptor QD

Part A: Dose escalation

4 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle.

If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Drug: FGF Receptor
LY2874455 administered orally.
Other Name: LY2874455

Experimental: Part A: 10 mg FGF Receptor QD

Part A: Dose escalation

10 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle.

If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days).

Drug: FGF Receptor
LY2874455 administered orally.
Other Name: LY2874455

Experimental: Part A: 10 mg FGF Receptor QD + Phosphate Binders

Part A: Dose escalation

10 mg FGF receptor + phosphate binders given QD for a minimum of (1) 28 day cycle.

If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Drug: FGF Receptor
LY2874455 administered orally.
Other Name: LY2874455

Drug: Phosphate Binders
Experimental: Part A: 8 mg FGF Receptor BID

Part A: Dose escalation

8 mg of FGF receptor given orally twice a day (BID) for a minimum of (1) 28 day cycle.

If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Drug: FGF Receptor
LY2874455 administered orally.
Other Name: LY2874455

Experimental: Part A: 10 mg FGF Receptor BID

Part A: Dose escalation

10 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.

If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Drug: FGF Receptor
LY2874455 administered orally.
Other Name: LY2874455

Experimental: Part A: 14 mg FGF Receptor BID

Part A: Dose escalation

14 FGF receptor given orally BID for a minimum of (1) 28 day cycle.

If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Drug: FGF Receptor
LY2874455 administered orally.
Other Name: LY2874455

Experimental: Part A: 18 mg FGF Receptor BID

Part A: Dose escalation

18 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.

If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Drug: FGF Receptor
LY2874455 administered orally.
Other Name: LY2874455

Experimental: Part A: 24 mg FGF Receptor BID

Part A: Dose escalation

24 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.

If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days).

Drug: FGF Receptor
LY2874455 administered orally.
Other Name: LY2874455

Experimental: Part A: 18 mg FGF Receptor BID Extension

Part A: Dose escalation

18 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.

If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Drug: FGF Receptor
LY2874455 administered orally.
Other Name: LY2874455

Experimental: Part A: 16 mg FGF Receptor BID

Part A: Dose escalation

16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.

If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Drug: FGF Receptor
LY2874455 administered orally.
Other Name: LY2874455

Experimental: Part B: 16 mg FGF Receptor BID

Part B: Dose determined by part a dose escalation

16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.

If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Drug: FGF Receptor
LY2874455 administered orally.
Other Name: LY2874455




Primary Outcome Measures :
  1. Recommended Dose for Phase 2 Studies : Maximum Tolerated Dose (MTD) [ Time Frame: Baseline Up to 32 Weeks ]
    MTD was determined after the evaluation of Part A portion of the trial. Dose escalation proceeded at 1.3 times the preceding cohort once a Grade 3 non-laboratory toxicity or Grade 2 laboratory toxicity was noted in ≥ 1 participant until MTD was achieved. Doses up to 24 mg (48 mg/day) were evaluated in Part A. The effects at this dose and at 18 mg (36 mg/day) suggested that a reasonable number of participants might not tolerate LY2874455 for chronic administration at these dose levels because of the constellation of effects observed individually or in combination in participants at these dose levels. Therefore, the dose of 16 mg BID of LY2874455 (total dose 32 mg per day) was selected as the initial dose for Part B. Selection of the dose level was based on the tolerability of this dose and without specific toxicities identified.


Secondary Outcome Measures :
  1. Number of Participants With Treatment-Emergent Adverse Events [ Time Frame: Baseline Up to 60 Weeks ]
    Treatment-emergent adverse events (TEAEs) are events which were not present at baseline or pre-existing conditions at baseline that worsened in severity following the start of treatment. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.

  2. Percentage of Participants With Best Overall Response Rate (BORR) and Objective Response Rate (ORR) [ Time Frame: BORR: Baseline Up to 60 Weeks ; ORR: Baseline Up to 60 Weeks ]

    BORR is evaluated using response evaluation criteria in solid tumors (RECIST, version 1.1) criteria. Complete Response (CR): disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to <10 millimeters (mm). Partial Response (PR): at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter.

    Best overall response rate = (unconfirmed CR+ unconfirmed PR) / subjects in efficacy population.

    Objective response rate = (confirmed CR+ confirmed PR) / subjects in efficacy population.


  3. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY2874455 [ Time Frame: Part A and B: Cycle 1, Day 1, Pre-Dose, 0.5 Hr (H), 1 H, 2 H, 4H,8 H,12 H,24 H; Day 28, Pre-Dose, 0.5 H, 1 H, 2 H, 4 H, 8 H ]
    Maximum observed concentration during a dosing interval.

  4. Pharmacokinetics (PK): Area Under the Concentration vs Time Curve 0 to Tau ( AUC[0-t]) of LY2874455 [ Time Frame: Part A and B: Cycle 1, Day 1, Pre-Dose, 0.5 Hr (H), 1 H, 2 H, 4H,8 H,12 H,24 H; Day 28, Pre-Dose, 0.5 H, 1 H, 2 H, 4 H, 8 H ]
    Area under the concentration-time curve from time 0 to the end of the dosing interval (e.g., BID) calculated by a combination of linear and logarithmic trapezoidal methods (linear-up/log-down method).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have histological or cytological evidence of a diagnosis of cancer (solid tumors, lymphoma, or chronic lymphocytic leukemia) that is advanced and/or metastatic and for which all standard therapies have failed
  • Have the presence of measurable or non-measurable disease
  • Have given written informed consent prior to any study-specific procedures
  • Have adequate organ function including:

    • Hematologic: Absolute neutrophil count (ANC) equal to or greater than 1.5 x 10(9)/L platelets equal to or greater than 100 x 10(9)/L, and hemoglobin equal to or greater than 8 g/dL. Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin until 14 days after the erythrocyte transfusion
    • Hepatic: Bilirubin equal to or less than 1.5 times upper limits of normal (ULN), alanine transaminase (ALT), and aspartate transaminase (AST) equal to or less than 2.5 times ULN. If the liver has tumor involvement, AST and ALT equaling equal to or less than 5 times ULN are acceptable
    • Renal: Serum creatinine less than or equal to 1.2 times ULN or calculated creatinine clearance greater than or equal to 60 milliliters per minute using the Standard Cockcroft and Gault Creatinine Clearance Calculation
    • Calcium and phosphate less than or equal to 1.1 times ULN
  • Have a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) scale
  • Have discontinued chemotherapy and cancer-related hormonal therapy with commercially available agents for at least 21 days (6 weeks for mitomycin-C or nitrosoureas) and radiotherapy for at least 14 days prior to study enrollment and recovered from the acute effects of therapy. Hormone refractory prostate cancer participants receiving gonadotropin releasing hormone (GnRH) agonist therapy or breast cancer participants on antiestrogen therapy (for example, an aromatase inhibitor) prior to entrance on the study may have that treatment continued while they are enrolled in the study
  • Females with childbearing potential must have had a negative serum pregnancy test less than or equal to 7 days prior to the first dose of study drug. Males and females with reproductive potential must agree to use 2 medically approved contraceptive methods during the trial and for 3 months following the last dose of study drug. Female participants must agree to use 2 medically acceptable methods of contraception, 1 being an oral contraceptive, dermal patch, or progestin (implantation or injection), and the other being a medically acceptable barrier method; alternatively, 2 medically acceptable barrier methods may be used. Medically acceptable barrier methods of contraception that may be used by the participant and/or his/her partner include: abstinence; diaphragm with spermicide; intrauterine device (IUD); condom together with foam, spermicide, or vaginal spermicidal suppository. Prohibited methods include the rhythm method, withdrawal, condoms alone, or diaphragm alone
  • Have an estimated life expectancy of greater than or equal to 12 weeks

Exclusion Criteria:

  • Have received treatment with an investigational drug, which has not received regulatory approval for any indication, within 28 days of study treatment with LY2874455
  • Currently taking agents to control serum phosphate or calcium levels. This includes dietary restrictions
  • Have medical conditions that, in the opinion of the investigator, would preclude participation in this study
  • Have symptomatic central nervous system (CNS) malignancy or metastasis. Participants with treated CNS metastases are eligible provided their disease is radiographically stable, asymptomatic, and they are not currently receiving corticosteroids and/or anticonvulsants. Screening of asymptomatic participants without history of CNS metastases is not required
  • Have a history of major organ transplant (for example: heart, lungs, liver, and kidney)
  • Have current acute leukemia
  • Females who are pregnant or nursing
  • An untreated or uncontrolled acute infection, including urinary tract infection, within 7 days of study entry
  • Have Bazett's corrected QT (QTcB) greater than 470 msec (female) or greater than 450 msec (male), history of unexplained recurrent syncope, history of congenital long QT syndrome, family history of sudden death, or the presence in the screening electrocardiogram (ECG) of a conduction abnormality that in the opinion of the investigator would preclude safe participation in this study
  • Have had an autologous or allogenic bone marrow transplant
  • Previously treated with LY2874455

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01212107


Locations
Layout table for location information
Australia, Victoria
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
East Melbourne, Victoria, Australia, 3002
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Parkville, Victoria, Australia, 3050
Korea, Republic of
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01212107     History of Changes
Other Study ID Numbers: 13843
I4R-MC-FGAA ( Other Identifier: Eli Lilly and Company )
First Posted: September 30, 2010    Key Record Dates
Results First Posted: June 12, 2019
Last Update Posted: June 12, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Eli Lilly and Company:
Advanced cancer
Metastatic cancer
Oncology
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms